Zydus receives Pre-Approval Inspection at the Ahmedabad API facility

Zydus Lifesciences Ltd has received Post Application Action Letter from the USFDA for the inspection conducted at the Ahmedabad API facility, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzylutamide from 14 -22 December 2023.

Advanced Enzyme Technologies increases stake in JC Biotech

Advanced Enzyme Technologies Limited has completed the acquisition of additional stake of 5.89% in JC Biotech Private Limited, subsidiary (JCB) by way of purchase of 12,18,976 Equity Shares from few selling shareholders of JCB, for a consideration of Rs. 5.60 crore i.e. Rs. 46 per Equity Share. In view of this, the shareholding of the Company in JCB has increased from 89.83% to 95.72% of paid-up share capital of JCB.

Link Pharma Chem purchases land Nadesari Industrial Estate

Link Pharma Chem Limited has purchased Plot no. 161 at Nandesari Industrial Estate, Nandesari Dist Vadodara admeasuring 796.75 sq. mtrs from Chloro Chem of India to facilitate manufacturing activities of the Company.

ANVISA issues CGMP to Concord Biotech’s Unit I

Brazilian Health Regulatory Agency (ANVISA) has Issued Certificate of Good Manufacturing Practices of our Unit I (API facility) of the Company, located at Trasad Road, Dholka - 382225 in Ahmedabad, Gujarat.